Aspire Biopharma
Developer of sublingual drug and supplement formulations, including aspirin candidates and Buzz Bomb.
Something off on this page? Send us feedback.
Profile
Develops sublingual formulations of known drugs and supplements, sells Buzz Bomb caffeine products, and advances a high-dose aspirin candidate. Current revenue is from nutraceutical sales, while potential pharmaceutical income depends on development, regulatory approval, and a contractor-led supply model.
Develops sublingual powder and granule formulations of known drugs and supplements, intended to support rapid absorption. Its product and development lines include the high-dose aspirin candidate for suspected acute myocardial infarction, Buzz Bomb caffeine supplement, low-dose aspirin, sublingual melatonin, vitamins D, E, and K, and exploratory drug formulations.
Generates current product revenue from nutraceutical sales and expects prospective revenue to include direct product sales, development funding, upfront and milestone payments, royalties, and licensing. Sales are primarily to U.S. customers, with smaller amounts in Canada and other geographies.
Relies on contract manufacturers for clinical and commercial supply, rather than owning manufacturing facilities. The delivery mechanism itself has not received FDA approval, while the lead aspirin program requires additional clinical development and has no established sales, marketing, or distribution infrastructure.
Company facts
Key statistics
Year to date −94.8% · Average volume (30d) 37.8K
Analysts
No analyst consensus on record.
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 13, 2026Q2 FY26 | — | −$1.00 | — | — | $63.1K | — | −0.28% |
| Aug 12, 2026Q2 FY26 | — | — | — | — | $63.1K | — | −6.31% |
| May 15, 2026Q1 FY26 | — | −$20.57 | — | — | $28.4K | — | +19.07% |
| Mar 30, 2026Q4 FY25 | — | −$3.15 | — | — | $4.3K | — | +8.42% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $1.9K | $4.3K | $28.4K | $63.1K | |
| Gross profit | $0 | $0 | $884 | −$1.0K | $5.8K | $12.3K | |
| Operating income | −$15.6M | −$799.9K | −$1.1M | −$1.8M | −$1.6M | −$2.4M | |
| Net income | −$15.9M | −$2.0M | −$1.9M | −$4.7M | −$3.2M | −$1.3M | |
| Diluted EPS | −$16.83 | −$1.61 | −$1.49 | −$3.15 | −$2.16 | −$1.22 | |
| Gross margin | — | — | 45.5% | -23.5% | 20.3% | 19.5% | |
| Operating margin | — | — | -59,015.8% | -43,403.5% | -5,806.0% | -3,880.6% |
Fiscal years (4-quarter sums)FY21 $0 · FY22 $0 · FY23 $0 · FY24 $0 · FY25 $6.2K
Revenue by product · Q1 FY26
Revenue by geography · Q2 FY26
Balance sheet, Jun 30, 2026Cash & short-term investments $12.2M · Total debt $0 · Total assets $13.5M · Shareholders' equity $11.8M
Dividends
No dividends on record.
Ownership
Shares outstanding 115.4K · Float 77.7K · 67.4% free float
A split settled inside the quarter being compared, so quarter-on-quarter change is not shown.
Insider tradesForm 4
Nothing filed in the last 12 months.
View detailsPeers
- Haleon (ADR)
OTC pain relief and faster-absorption formats via Advil.
- Kenvue
OTC analgesic rival through Tylenol pain-relief products.
- Aquestive Therapeutics
Sublingual drug-delivery platform benchmark using PharmFilm.
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Aspire Biopharma | $8.51 | −0.12% | $981.8K | — | — | 10.1 | — |
| Haleon (ADR) | $10.11 | +0.05% | $44.52B | 20.7 | 10.8 | 2.9 | +3.7% |
| Kenvue | $19.17 | +0.03% | $36.81B | 22.0 | 16.0 | 2.4 | +3.0% |
| Aquestive Therapeutics | $5.02 | 0.00% | $629.8M | — | — | 11.6 | +38.2% |
| Median | 21.4 | 13.4 | 2.9 | +3.7% |